Prenatal treprostinil crosses the placenta in rats and is well tolerated by mother and fetus

Abstract

Prenatal therapy with prostanoids is considered as a potential non-invasive treatment strategy for congenital diaphragmatic hernia (CDH). Before assessing the efficacy of the drug in a rat disease model, transplacental transfer as well as fetal and maternal tolerance to the drug need to be demonstrated.